European Journal of Cancer
Volume 46, Issue 3 , Pages 616-624 , February 2010

COX-2 expression in chondrosarcoma: A role for celecoxib treatment?

  • Y.M. Schrage

      Affiliations

    • Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • I. Machado

      Affiliations

    • Department of Pathology, University of Valencia, Valencia, Spain
    • ,
  • D. Meijer

      Affiliations

    • Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • I. Briaire-de Bruijn

      Affiliations

    • Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • B.E. van den Akker

      Affiliations

    • Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • A.H.M. Taminiau

      Affiliations

    • Department of Orthopedic Surgery, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • T. Kalinski

      Affiliations

    • Department of Pathology, Otto-von-Guericke-University, Magdeburg, Germany
    • ,
  • A. Llombart-Bosch

      Affiliations

    • Department of Pathology, University of Valencia, Valencia, Spain
    • ,
  • J.V.M.G. Bovée

      Affiliations

    • Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    • Corresponding Author InformationCorresponding author: Address: Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands. Tel.: +31 715266617; fax: +31 715266952.

Received 4 September 2009 ,Accepted 10 November 2009.

References 

  1. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977;40:818–831
  2. Brien EW, Mirra JM, Luck JV. Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. II. Juxtacortical cartilage tumors.. Skeletal Radiol. 1999;28:1–20
  3. Bertoni F, Bacchini P, Hogendoorn PCW. Chondrosarcoma. In:  Fletcher CDM,  Unni KK,  Mertens F editor. World Health Organisation classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002;p. 247–251
  4. Lucas DR, Bridge JA. Chondromas: enchondroma, periosteal chondroma, and enchondromatosis. In:  Fletcher CDM,  Unni KK,  Mertens F editor. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002;p. 237–240
  5. Ollier M. Dyschondroplasie. Lyon Med. 1900;93:23–25
  6. Schwartz HS, Zimmerman NB, Simon MA, Wroble RR, Millar EA, Bonfiglio M. The malignant potential of enchondromatosis. J Bone Joint Surg Am. 1987;69:269–274
  7. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New Engl J Med. 2000;342:1946–1952
  8. van Stolk R, Stoner G, Hayton WL, et al. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res. 2000;6:78–89
  9. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. New Engl J Med. 2003;348:891–899
  10. Smith WL, Marnett LJ, DeWitt DL. Prostaglandin and thromboxane biosynthesis. Pharmacol Ther. 1991;49:153–179
  11. Endo M, Matsumura T, Yamaguchi T, et al. Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcomas. Hum Pathol. 2006;37:471–476
  12. Sutton KM, Wright M, Fondren G, Towle CA, Mankin HJ. Cyclooxygenase-2 expression in chondrosarcoma. Oncology. 2004;66:275–280
  13. Bovée JVMG, Cleton-Jansen AM, Kuipers-Dijkshoorn N, et al. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chrom Cancer. 1999;26:237–246
  14. Baelde HJ, Cleton-Jansen AM, van Beerendonk H, et al. High quality RNA isolation from tumours with low cellularity and high extracellular matrix component for cDNA microarrays: application to chondrosarcoma. J Clin Pathol. 2001;54:778–782
  15. Hameetman L, Rozeman LB, Lombaerts M, et al. Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog (IHH) signalling. J Pathol. 2006;209:501–511
  16. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3;research0034.1–0034.11
  17. Gil-Benso R, Lopez-Gines C, Lopez-Guerrero JA, et al. Establishment and characterization of a continuous human chondrosarcoma cell line, ch-2879: comparative histologic and genetic studies with its tumor of origin. Lab Invest. 2003;83:877–887
  18. Kunisada T, Miyazaki M, Mihara K, et al. A new human chondrosarcoma cell line (OUMS-27) that maintains chondrocytic differentiation. Int J Cancer. 1998;77:854–859
  19. Kalinski T, Krueger S, Pelz AF, et al. Establishment and characterization of the permanent human cell line C3842 derived from a secondary chondrosarcoma in Ollier’s disease. Virchows Arch. 2005;446:287–299
  20. Cleton-Jansen AM, van Beerendonk HM, Baelde HJ, et al. Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res. 2005;11:8028–8035
  21. Schrage YM, Briaire-de Bruijn IH, de Miranda NFCC, et al. Kinome profiling of chondrosarcoma reveals Src-pathway activity and dasatinib as option for treatment. Cancer Res. 2009;69:6216–6222
  22. de Heer P, Sandel MH, Guertens G, et al. Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. Cancer Chemother Pharmacol. 2008;62:811–819
  23. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006;98:736–747
  24. Su B, Diaz-Cruz ES, Landini S, Brueggemeier RW. Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids. 2008;73:104–111
  25. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med. 2005;352:1071–1080
  26. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl J Med. 2005;352:1092–1102
  27. Frampton JE, Keating GM. Celecoxib: a review of its use in the management of arthritis and acute pain. Drugs. 2007;67:2433–2472

PII: S0959-8049(09)00839-9

doi: 10.1016/j.ejca.2009.11.002

European Journal of Cancer
Volume 46, Issue 3 , Pages 616-624 , February 2010

Article Tools

* Image Usage & Resolution